Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 40.50% and 41.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
by Zacks Equity Research
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
Why Vertex (VRTX) Might Surprise This Earnings Season
by Zacks Equity Research
Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $233.91, moving -0.3% from the previous trading session.
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $226.49, moving -1.07% from the previous trading session.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $223.79 in the latest trading session, marking a -0.11% move from the prior day.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $218.95, moving -0.01% from the previous trading session.
The Zacks Analyst Blog Highlights: Medtronic, United Technologies, Union Pacific, Vertex Pharmaceuticals and NextEra Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, United Technologies, Union Pacific, Vertex Pharmaceuticals and NextEra Energy
Top Research Reports for Medtronic, United Technologies & Union Pacific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Medtronic (MDT), United Technologies (UTX) and Union Pacific (UNP).
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $219.98, moving -0.32% from the previous trading session.
Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
New Strong Buy Stocks for December 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
3 Tech Stocks for Growth Investors to Buy for 2020
by Benjamin Rains
Check out three tech stocks we found with our Zacks Stock Screener that growth investors might want to consider buying for 2020...
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Biotech Stock Outlook: M&A Activity Retains Growth Streak
by Ekta Bagri
The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $217.62, marking a -0.86% move from the previous day.
New Strong Buy Stocks for December 16th
by Tirthankar Chakraborty
Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Stocks Hit Records on China Trade Hope & Buy this Biotech Stock - Free Lunch
by Benjamin Rains
The latest U.S-China trade war news that includes a positive tweet from President Trump that helped lift stocks to new highs. A look at LULU's earnings. And why Vertex Pharmaceuticals (VRTX) is a Zacks Rank #1 (Strong Buy) stock right now...
New Strong Buy Stocks for December 12th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday.
Vertex's Kalydeco Gets EU Approval to Treat CF in Infants
by Zacks Equity Research
Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.
Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice
by Zacks Equity Research
Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.